Turning Microbial Genetics into Medicine
Overview.
Second Genome is a clinical stage pharmaceutical company with a mission to translate microbiome science into a pipeline of therapeutics across a range of indications. We leverage our proprietary drug discovery platform to identify effective proteins and small molecule therapeutics derived from the microbiome. We built a proprietary platform turning microbial genetics into precision therapeutics and have cracked the microbiome code. We are advancing a pipeline of precision therapeutics and biomarkers. We are delivering on collaborations and poised for more. We are ready to make a difference for patients.
Platform
Second Genome's proprietary Microbiome Discovery Platform uniquely addresses current limitations in target discovery and validation by:
- Integrating computational science and machine learning with human disease biology to redefine diseases
- Building and maintaining structured databases of public and proprietary datasets
- Generating libraries of compounds that are screened in traditional drug discovery and development assays
Pipeline
Our lead program, SG-2-0776, is a novel therapeutic protein derived from the microbiome that promotes mucosal healing of damaged epithelial surfaces. SG-2-0776 is currently in pre-clinical and IND-enabling studies, and we plan to initiate clinical development.
SG-2-0776
Inflammatory bowel disease (IBD) is a diverse disease of unknown etiology resulting in more frequent and bloody bowel movements accompanied with histopathological damage to the gastrointestinal mucosa.
Location
341 Allerton Avenue, South San Francisco, CA 94080, USA
Contact us
Want to learn more about Second Genome or have a question about our approach? Use the contact form and let’s start a conversation.